UNCY

+ Watchlist + Portfolio

Unicycive Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.58
52-Week Range: $3.71 – $8.74
Market Cap: $149.29M
P/E (TTM): —
EPS (TTM): -1.75
Dividend Yield: —

Advanced Metrics

Price/Book: 2.85
PEG Ratio: —
Return on Equity: -101.07%
Return on Assets: -40.59%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 3.81
Debt/Equity: 0.01
Total Debt: $671.00K
Free Cash Flow: $-12.72M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $94.68M

UNCY Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$951.00K	$675.00K	$0.00	$0.00
Research & Development	$12.44M	$12.90M	$20.01M	$9.12M
Selling, General & Admin	$6.57M	$8.55M	$12.10M	$20.40M
Operating Expenses	$19.00M	$21.45M	$32.12M	$29.52M
Operating Income	-$18.05M	-$20.77M	-$32.12M	-$29.52M
EBITDA	-$17.89M	-$30.18M	-$36.23M	-$25.91M
Pretax Income	-$18.06M	-$30.54M	-$36.73M	-$26.55M
Net Income	-$18.06M	-$30.54M	-$36.73M	-$26.55M
Diluted EPS	-12.00	-12.80	-5.65	-1.67
Diluted Shares	1.51M	2.45M	6.70M	15.89M

UNCY Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$455.00K	$9.70M	$26.14M	$29.20M
Current Assets	$2.64M	$13.40M	$30.95M	$48.96M
Total Assets	$2.82M	$14.19M	$31.67M	$49.13M
Current Liabilities	$3.28M	$17.53M	$24.12M	$18.94M
Total Debt	$201.00K	$811.00K	$773.00K	$199.00K
Total Liabilities	$3.28M	$18.00M	$24.24M	$18.94M
Retained Earnings	-$34.00M	-$64.54M	-$101.27M	-$127.83M
Shareholders' Equity	-$466.00K	-$3.81M	$7.43M	$30.20M
Working Capital	-$640.00K	-$4.13M	$6.83M	$30.02M

UNCY Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.65M	-$18.28M	-$28.57M	-$31.32M
Capital Expenditure	-$2.00K	-$12.00K	-$72.00K	-$24.00K
Free Cash Flow	-$15.65M	-$18.30M	-$28.65M	-$31.34M
Depreciation & Amortisation	$161.00K	$284.00K	$428.00K	$572.00K
Stock-Based Compensation	$1.05M	$1.77M	$2.35M	$2.64M
Investing Cash Flow	-$2.00K	-$12.00K	-$72.00K	-$12.10M
Financing Cash Flow	-$471.00K	$27.54M	$45.09M	$46.47M
Dividends Paid	—	$0.00	-$1.09M	$0.00
Net Change in Cash	-$16.12M	$9.25M	$16.44M	$3.06M

UNCY Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.17M	$1.75M	$2.96M	$2.25M	$1.61M
Selling, General & Admin	$5.82M	$5.21M	$4.38M	$4.97M	$6.83M
Operating Expenses	$7.99M	$6.96M	$7.34M	$7.22M	$8.44M
Operating Income	-$7.99M	-$6.96M	-$7.34M	-$7.22M	-$8.44M
EBITDA	$720.00K	-$6.30M	-$5.85M	-$14.49M	-$12.61M
Pretax Income	$570.00K	-$6.45M	-$6.01M	-$14.67M	-$12.82M
Net Income	$570.00K	-$6.45M	-$6.01M	-$14.67M	-$12.82M
Diluted EPS	-0.50	-0.52	-0.33	—	-0.54
Diluted Shares	12.38M	12.30M	18.07M	—	23.91M

UNCY Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$19.77M	$22.33M	$42.70M	$29.20M	$37.37M
Current Assets	$27.35M	$29.53M	$50.29M	$48.96M	$63.55M
Total Assets	$27.95M	$30.00M	$50.61M	$49.13M	$64.41M
Current Liabilities	$16.68M	$13.57M	$13.13M	$18.94M	$26.48M
Total Debt	$694.00K	$476.00K	$505.00K	$199.00K	$941.00K
Total Liabilities	$16.68M	$13.57M	$13.13M	$18.94M	$26.70M
Retained Earnings	-$100.70M	-$107.15M	-$113.16M	-$127.83M	-$140.65M
Shareholders' Equity	$11.27M	$16.43M	$37.48M	$30.20M	$37.70M
Working Capital	$10.67M	$15.96M	$37.16M	$30.02M	$37.06M

UNCY Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.90M	-$8.42M	-$5.96M	-$8.03M	-$6.24M
Capital Expenditure	-$16.00K	-$6.00K	-$2.00K	—	-$8.00K
Free Cash Flow	-$8.92M	-$8.43M	-$5.96M	-$8.03M	-$6.25M
Depreciation & Amortisation	$135.00K	$138.00K	$148.00K	$151.00K	$211.00K
Stock-Based Compensation	$563.00K	$571.00K	$730.00K	$777.00K	$754.00K
Investing Cash Flow	-$16.00K	-$6.00K	-$2.00K	-$12.07M	-$5.16M
Financing Cash Flow	$2.55M	$10.98M	$26.33M	$6.61M	$19.57M
Dividends Paid	—	—	$0.00	$0.00	—
Net Change in Cash	-$6.37M	$2.56M	$20.37M	-$13.50M	$8.17M

Market Snapshot

About

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The company focuses on novel therapies for acute kidney injury, chronic kidney disease, and renal complications in rare genetic disorders. Unicycive is advancing multiple drug candidates through clinical development targeting unmet needs in nephrology.